Plenary Speakers

Mid-Atlantic Bio consistently attracts the best and the brightest speakers within the bioscience field.  We are pleased to announce our plenary speakers:

Opening Plenary
Thursday, September 27, 2012
10:20 AM

Patrick J. Mahaffy, Co-founder, President and CEO of Clovis Oncology

Patrick J. Mahaffy is one of the co-founders of Clovis Oncology and has served as the President and CEO and on the board of directors since the Company’s inception. Prior to founding Clovis, Mr. Mahaffy served as President and CEO and on the board of directors at Pharmion Corporation, which he founded in 2000 and sold to Celgene Corporation in 2008. From 1992 – 1998, Mr. Mahaffy was President and CEO of NeXagen, Inc. and its successor, NeXstar Pharmaceuticals, Inc. Prior to NeXagen, Mr. Mahaffy was a Vice President at the private equity firm E.M. Warburg Pincus and Co. Mr. Mahaffy serves on the boards of directors of Orexigen Therapeutics, Inc. (NASDAQ: OREX) and Flexion Therapeutics, Inc. Additionally, he is a trustee of Lewis and Clark College. Mr. Mahaffy has a B.A. in international affairs from Lewis and Clark College and a M.A. in international affairs from Columbia University.

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets. Clovis Oncology targets its development programs at specific subsets of cancer populations, and simultaneously develops diagnostic tools that direct a compound in development to the population that is most likely to benefit from its use. Clovis Oncology is headquartered in Boulder, Colorado, and has additional offices in San Francisco, California and Cambridge, UK.

_______________________________________________________________________________

Plenary Panel: Seeing a Bright Future:  What’s Ahead for an Ever-Changing Life Sciences Industry
Thursday, September 27, 2012
1:40 PM

Moderator: Steve Usdin, Senior Editor, BioCentury

Steve has been Washington Editor of BioCentury since 1993, and has spent the past 20 years in the nation’s capital covering political and policy issues affecting the life sciences sector. He also is the host of BioCentury This Week, BioCentury’s weekly public affairs television program, as well as BioCentury Senior Editor responsible for coverage of social issues involving biotechnology. Steve’s reporting about biotechnology and biomedical policy has been cited in The Economist, The Wall Street Journal, the Washington Post, New Scientist and other publications. In 2012, the FDA Alumni Association named Steve the Harvey W. Wiley Lecturer, making him the first journalist to receive the Wiley Award. His book, “Engineering Communism: How Two Americans Spied for Stalin and Founded the Soviet Silicon Valley,” was published in 2005 by Yale University Press.

Panelist: M. James Barrett Ph.D., General Partner, New Enterprise Associates (NEA)

Jim joined NEA in 2001 as a General Partner. He specializes in biotechnology and works with members of NEA’s healthcare investment group on medical devices and specialty pharmaceutical companies. Present board memberships include Amicus Therapeutics, Cardioxyl Pharmaceuticals, Clovis Oncology, GlycoMimetics, Inc., PhaseBio Pharmaceuticals, Predictive Biosciences, Psyadon Pharmaceuticals, Roka Bioscience, Sensors for Medicine and Science, Inc., Supernus Pharmaceuticals, Inc., Targacept, Inc. (NASDAQ: TRGT) and Zosano Pharma, Inc. Jim formerly served on the boards of CoGenesys (acquired by Teva Pharmaceutical Industries), Iomai Corporation (acquired by Intercell AG), MedImmune, Inc. (acquired by AstraZeneca) and Pharmion (acquired by Celgene). Prior to NEA, Jim served as Founder, Chairman and CEO of Sensors for Medicine and Science (1997 – 2001). Prior to that, he led three NEA-funded companies, serving as Chairman and CEO of Genetic Therapy, Inc. (1987 – 1995), President and CEO of Life Technologies (1985 – 1987), and President and CEO of Bethesda Research Labs (1982 – 1983). Prior to 1982, Jim worked in various divisions of SmithKline. Jim received a PhD in Biochemistry at the University of Tennessee, his MBA from the University of Santa Clara, and a BS in Chemistry from Boston College.

Panelist: Vicki Seyfert-Margolis, Ph.D., Senior Advisor to Chief Scientist, FDA

Vicki L. Seyfert-Margolis, Ph.D., is Senior Advisor for Science Innovation and Policy in the FDA Commissioner’s Office. Dr. Seyfert-Margolis focuses on initiatives in innovation, regulatory science, personalized medicine, scientific computing and health informatics. Previously, she served as Chief Scientific Officer at Immune Tolerance Network (ITN), a non-profit consortium of researchers seeking new treatments for diseases of the immune system. At ITN, she oversaw the development of more than 20 centralized laboratory facilities, and the design and execution of biomarker discovery studies for over 25 Phase II clinical trials. As part of the biomarker efforts she established construction of a primer library of 1,000 genes that may be involved in establishing and maintaining immunologic tolerance and co-discovered genes that may mark kidney transplant tolerance. Dr. Seyfert-Margolis was also an Adjunct Associate Professor with the Department of Medicine at the University of California San Francisco. Prior to academia, she served as Director of the Office of Innovative Scientific Research Technologies at the National Institute of Allergy and Infectious Diseases at NIH, where she worked to integrate emerging technologies into existing immunology and infectious disease programs. Dr. Seyfert-Margolis completed her PhD in immunology at the University of Pennsylvania’s School of Medicine.

Panelist: Ron Cohen M.D., President, CEO and Founder of Acorda Therapeutics, Inc.

Ron Cohen, M.D. is President, CEO and founder of Acorda Therapeutics, Inc., a public biotechnology company developing therapies for spinal cord injury, multiple sclerosis and other disorders of the central nervous system. Dr. Cohen previously was a principal in the startup and an officer of Advanced Tissue Sciences, Inc., a biotechnology company engaged in the growth of human organ tissues for transplantation uses. Dr. Cohen is Chairman of the Emerging Company Board of the Biotechnology Industry Organization (BIO) and is a member of the Executive Committee of the BIO Board. He previously served as Director and Chairman of the New York Biotechnology Association. He also serves as a member the Columbia-Presbyterian Health Sciences Advisory Council and was awarded Columbia University’s Alumni Medal for Distinguished Service.

Dr. Cohen was named Neuroinvestment’s CEO of the Year, is a recipient of the Ernst & Young Entrepreneur of the Year Award for the New York Metropolitan Region, and of the American Business Awards (ABA) Stevie Award as Executive of the Year in Health Products & Services. He is an inductee of the National Spinal Cord Injury Association’s “Spinal Cord Injury Hall of Fame” and received the Burke Award from Burke Rehabilition Hospital for his contributions to helping people with disabilities gain independence. Dr. Cohen has been recognized by the New York Biotechnology Association as the NYBA “The Cures Start Here” Business Leader of the Year, and was named one of the 100 Most Inspirational People in the Biopharmaceutical Industry by PharmaVOICE Magazine.

Dr. Cohen received his B.A. degree with honors in Psychology from Princeton University, and his M.D. from the Columbia College of Physicians & Surgeons. He completed a residency in Internal Medicine at the University of Virginia Medical Center, and is Board Certified in Internal Medicine.

_______________________________________________________________________________

Capstone Plenary Panel: The Business of Health Delivery from Leaders of Today’s Hospital Systems
Thursday, September 27, 2012
4:30 PM

Moderator: Bruce Robertson Ph.D., Managing Director, H.I.G. BioVentures

Bruce Robertson is a Managing Director of H.I.G. BioVentures, the life science focused venture capital affiliate of H.I.G. Capital, a $10 billion global private equity firm. H.I.G. BioVentures, which closed a new $270 million fund in 2012, focuses on investment opportunities in biopharmaceuticals, medical devices, and diagnostics. He currently serves on the boards of CardioFocus, Apollo Endosurgery, and Clarus Therapeutics.

Bruce has been active in the life sciences sector for more than 20 years. Prior to joining H.I.G., Bruce served most recently as Managing Director at Toucan Capital, an early-stage venture capital fund in Maryland, focusing on life science investments. While at Toucan, Bruce invested in leading drug and device companies throughout the U.S. Prior to Toucan, Bruce was a General Partner at GIV Venture Partners, a venture capital firm focused on early stage investments in the US, India, and China. Prior to his venture capital career, Bruce was Director of Business Development at IGEN International, where he was responsible for formulating and implementing IGEN’s partnering and M&A strategies. Bruce started his career as a Research Manager at W.R. Grace & Co., focusing on medical devices.

Bruce is on the boards of the Mid-Atlantic Venture Association, Adventist Healthcare, the BioLife Fund of Virginia’s Center for Innovative Technology, and the University of Delaware Research Foundation. Bruce holds a BSE in Chemical Engineering and BA in Mathematics from the University of Pennsylvania, a PhD in Chemical/Biomedical Engineering from the University of Delaware, and an MBA with High Distinction from Harvard Business School.

Panelist: William G. “Bill” Robertson, President and CEO of Adventist HealthCare, Inc.

William G. “Bill” Robertson is the President and CEO of Adventist HealthCare, Inc., which operates Washington Adventist Hospital, Hackettstown Regional Medical Center, Shady Grove Adventist Hospital, Adventist Behavioral Health, Adventist Rehabilitation Hospital of Maryland, Adventist Home Health, and a number of other health care services. Based in Rockville, Adventist HealthCare is one of the largest private employers in Montgomery County, employing more than 6,500 people and caring for nearly 450,000 patients each year. Robertson has served as President and CEO of this non-profit corporation since the spring of 2000 and has been a health care executive for the past 27 years.

Prior to joining Adventist HealthCare, Inc., Robertson served for four years as the Chief Executive Officer of Shawnee Mission Medical Center, one of the largest and most preferred hospitals in the Kansas City area and he was the Executive Vice President and CFO of Huguley Health System in Fort Worth, Texas from 1988 to 1996.

Robertson received a Bachelor of Science in Accounting from Southern Adventist University and a Master of Business Administration from Texas Christian University.

Robertson is involved with a number of community organizations including BioHealth Innovation, Inc. Board; The Governor’s Workforce Investment Board; The Governor’s P- 20 Leadership Council of Maryland; The Maryland Workforce Corporation Board; Montgomery County Chamber of Commerce Board and Economic Development Committee; Strathmore Hall Foundation Board and Washington Adventist University Board of Trustees.

Panelist: J. Knox Singleton, CEO of Inova Health System

J. Knox Singleton is Chief Executive Officer of Inova Health System, one of the nation’s most integrated and most wired healthcare delivery systems and one of the largest in the metropolitan Washington region.

Through Mr. Singleton’s stewardship for the past 25 years, Inova Health System has pursued its not-for-profit mission of providing world-class healthcare to all members of its diverse Northern Virginia community, regardless of ability to pay. For 13 of the past 14 years, U.S. News & World Report has named Inova Fairfax Hospital, Inova’s flagship facility, as one of “America’s Best Hospitals.” (For more information on other awards received by the System for its care, see inova.org/awards.)

Mr. Singleton was first named to lead the organization in 1984 when it was called the Fairfax Hospital Association. He joined the Fairfax Hospital Association as executive vice president for operations in 1983.

During his tenure, he has led Inova through a period of significant growth and expansion that continues today. Inova now comprises hospitals, nursing homes, emergency- and urgent-care centers, assisted-living communities, a home health agency, community health and wellness programs, and various community clinics.

Mr. Singleton is a director and officer of a variety of community organizations that address issues such as affordable housing and human services. He is a trustee of Maryville College in Maryville, TN and Wesley Theological Seminary where he also serves as Chair of Wesley Finance Committee. He serves on the board of directors of Washington Mutual Investment Funds, JPMorgan Value Opportunities Fund and Healthcare Realty Trust. He serves as president for the Community Coalition for Haiti and is a Ruling Elder of Vienna Presbyterian Church. Mr. Singleton also served on the George Mason University’s Board of Visitors. He was named 1990 Citizen of the Year by The Washington Post and received the 1993 Community Care Award for Health from the Northern Virginia Community Foundation. In 2000, he received the distinguished Regent’s Award from the American College of Healthcare Executives (ACHE), and that year also received the Distinguished Leadership Award from the Washington Chapter of the American Jewish Committee. In 2004, he received the distinguished Governor’s Award from Virginia Gov. Mark Warner, recognizing Mr. Singleton’s outstanding leadership in business and education partnerships. In November 2009, he was inducted into the Washington Business Hall of Fame, established in 1988 by Washingtonian magazine, the Greater Washington Board of Trade, and Junior Achievement of the National Capital Area.

Before joining Inova, Mr. Singleton served as the hospital director for the Hershey Medical Center of Pennsylvania State University in Hershey,PA, from 1978 to 1983. He was the assistant director of the Medical Center from 1975 to 1977. His first position in the healthcare field was in administration for the English National Health Service, at Guy’s Hospital in London, England.

He is a Phi Beta Kappa graduate of the University of North Carolina, where he earned a Bachelor of Science Degree in Business Administration in 1970. He received his Master’s Degree in Health Administration fromDuke University in 1973. Mr. Singleton also has received honorary degrees from Northern Virginia Community College and Cumberland College in Williamsburg, KY.

Mr. Singleton is married, has four children and lives in Oakton,VA.

_______________________________________________________________________________

Closing Luncheon Plenary
Friday, September 28, 21012
12:30 PM

Peter Greenleaf, President of MedImmune

Peter Greenleaf is the President of MedImmune, the worldwide biologics arm for AstraZeneca. Mr. Greenleaf is responsible for leading one of the largest biotechnology employers in the region, and one of the founding companies of the mid-Atlantic biocluster.

Since becoming president in February 2010, Mr. Greenleaf has helped to shape MedImmune into an innovation-focused company that is poised to be the next revolutionary force in biotechnology. Under Mr. Greenleaf’s leadership, MedImmune has: continued to experience rapid growth, adding nearly 700 employees and expanding the reach of each of MedImmune’s campuses worldwide; opened an award-winning manufacturing facility in Frederick, Md.; struck a biotech-industry-first manufacturing capacity sharing deal with a major pharmaceutical company; presided over the expansion of MedImmune’s solid pipeline; and oversaw a steady stream of industry-leading business development and venture deals that will ensure MedImmune’s continued success.

Prior to becoming president, Mr. Greenleaf led the development of the company’s global marketing and portfolio organizations, as well as managed the broader commercial, corporate development and strategy functions.

In addition to his duties at MedImmune, Mr. Greenleaf chairs the Maryland Venture Fund Authority. Appointed by Governor Martin O’Malley in August 2011, Mr. Greenleaf leads the Authority’s charge to implement the InvestMaryland Program, the state’s largest venture capital investment initiative that aims to spur job creation, fuel investment and innovation and revitalize venture capital funding. Adding to his external accolades, Mr. Greenleaf was also recently named as an “Influential Marylander” by The Daily Record for his impact on Maryland’s business community and the success he has brought to the region. Mr. Greenleaf also serves on the board of trustees of the University of Maryland Baltimore Foundation, and the board of directors of the Biotechnology Industry Organization (BIO), the world’s largest biotech trade organization.

Mr. Greenleaf joined MedImmune from Centocor, Inc., where he served as vice president of the gastroenterology franchise, responsible for sales, marketing, strategic planning and business development. He joined Centocor’s cardiovascular division in 1998 and later moved into the immunology business, holding a number of positions with increasing responsibility. Previously, he was employed in key roles with Boehringer Mannheim Corporation and US Healthcare, Inc.

Mr. Greenleaf holds a Bachelor of Science degree from Western Connecticut State University and a Master’s degree in business administration from St. Joseph’s University.